Clinical pattern and risk factors for dyskinesias following fetal nigral transplantation in parkinson's disease: A double blind video-based analysis

Movement Disorders

Volumn 24, Issue 3, 2009, Pages 336-343

  Olanow, C Warren ^a   Gracies, Jean Michel ^a   Goetz, Christopher G ^b   Stoessl, A Jon ^c   Freeman, Thomas ^d   Kordower, Jeffrey H ^b   Godbold, James ^a   Obeso, Jose A ^e  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^d UNIVERSITY OF SOUTH FLORIDA   (United States)

^e UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Dyskinesia; Fetal nigral transplantion; Parkinson's disease

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT;

ADULT; ARTICLE; BRAIN TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; DRUG USE; DYSKINESIA; FEMALE; FETAL NIGRAL TRANSPLANTATION; HUMAN; LEG MOVEMENT; MALE; MORNING DOSAGE; MOTOR DYSFUNCTION; OUTCOME ASSESSMENT; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SCORING SYSTEM; TREATMENT RESPONSE; UNIFIED PARKINSON DISEASE RATING SCALE; VIDEORECORDING; CELL TRANSPLANTATION; CYTOLOGY; HOSPITALIZATION; METHODOLOGY; MIDDLE AGED; PRENATAL DEVELOPMENT; SUBSTANTIA NIGRA; TRANSPLANTATION;

ANTIPARKINSON AGENTS; CELL TRANSPLANTATION; DOUBLE-BLIND METHOD; DYSKINESIA, DRUG-INDUCED; DYSKINESIAS; FEMALE; HUMANS; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; VIDEOTAPE RECORDING;

EID: 67349088356     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.22208     Document Type: Article

References (36)

1. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(Suppl 1):2-11.
2. Lhermitte F, Agid Y, Signoret JL, Studler JM. Beginning and end of dose dyskinesias caused by L-dopa. Rev Neurol 1977;133:297-308.
3. Muenter MD, Sharpless NS, Tyce GM, Darley FL. Patterns of dystonia ("I-D-I" and "D-I-D-") in response to L-dopa therapy for Parkinson's disease. Mayo Clin Proc 1977;52:163-174.
4. Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord 1992;7:117-122.
5. De Saint Victor JF, Pollak P, Gervason CL, Perret J. Levodopa-induced diphasic dyskinesias improved by subcutaneous apomorphine. Mov Disord 1992;7:283-284.
6. Marconi R, Lefebre-Caparros D, Bonnet AM, Vidailhet M, Dubois B, Agid Y. Levodopa-induced dyskinesias in Parkinson's disease: phenomenology and pathophysiology. Mov Disord 1994; 9:2-12.
7. Fahn S. Fluctuations of disability in Parkinson's disease: pathophysiology. In: Marsden CD, Fahn S, editors. Movement disorders. London: Butterworth; 1981. p 123-145.
8. Freed CR, Greene PE, Breeze RE, et al. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001;344:710-719.
9. Hagell P, Piccini P, Bjorklund A, et al. Dyskinesias following neural transplantation in Parkinson's disease. Nat Neurosci 2002;5:627-628.
10. Olanow CW, Goetz CG, Kordower JH, et al. A double blind placebo-controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003;54:403-414.
11. Cubo E, Gracies JM, Benabou R, et al. Early morning "off-medication" dyskinesias, dystonia, and choreic subtypes. Arch Neurol 2001;58:1379-1382.
12. Winkler C, Kirik D, Björklund A. Cell transplantation in Parkinson's disease: how can we make it work? Trends Neurosci 2005;28:86-92.
13. Dunnet SB, Bjorklund A, Lindvall O. Cell therapy in Parkinson's disease - stop or go? Nat Rev Neurosci 2001;2:365-369.
14. Bjorklund A, Dunnet SB, Brundin P, et al. Neural transplantation for the treatment of Parkinson's disease. Lancet Neurol 2003; 2:437-445.
15. Olanow CW, Fahn S. Fetal nigral transplantation for parkinson's disease current status and future directions. In: Brundin P, Olanow CW, editors. Restorative therapies for Parkinson's disease. New York: Springer; 2006. p 93-118.
16. Goetz CG, Stebbins GT, Shale HM, et al. Utility of an objective dyskinesia rating scale for Parkinson's disease: inter-and intra-rater reliability assessment. Mov Disord 1994;9:390-394.
17. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research, 4th ed. London: Blackwell Science; 2002.
18. Greene PE, Fahn S, Tsai WY, et al. Severe spontaneous dyskinesias: a disabling complication of embryonic dopaminergic tissue implants in a subset of transplanted patients with advanced Parkinson's disease. Mov Disord 1999;14:904.
19. Ma Y, Feigin A, Dhawan V, et al. Dyskinesia after fetal cell transplantation for parkinsonism: a PET study. Ann Neurol 2002;52:628-634.
20. Kordower JH, Freeman TB, Snow BJ, et al. Neuropathologic evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease. N Eng J Med 1995;332:1118-1124.
21. Kordower JH, Rosenstein JM, Collier TM, et al. Functional fetal nigral grafts in a patient with Parkinson's disease: chemoanatomic, quantatative, ultrastructural, and metabolic studies. J Comp Neurol 1996;370:203-230.
22. Olanow CW, Obeso JA, Stocchi F. Continuous dopamine-receptor treatment of Parkinson's disease: scientific rationale and clinical implications. Lancet Neurol 2006;5:677-687.
23. De la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson's disease: implications for dyskinesias. Brain 2004;127:2747-2754.
24. Lee CS, Cenci MA, Schulzer M, Bjorklund A. Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain 2000;123:1365-1379.
25. Carlsson T, Winkler C, Burger C, et al. Reversal of dyskinesias in an animal model of Parkinson's disease by continuous L-dopa delivery using rAAV vectors. Brain 2005;128:559-569.
26. Bankiewicz KS, Daadi M, Pivirotto P, et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol 2006;197:363-372.
27. Maries E, Kordower JH, Chu Y, et al. Focal not widespread grafts induce novel dyskinetic behavior in parkinsonian rats. Neurobiol Dis 2006;21:165-180.
28. Bankiewicz KS, Daadi M, Pivirotto P, et al. Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys. Exp Neurol 2006;197:363-372.
29. Carlsson T, Winkler C, Lundblad M, et al. Graft placement and uneven pattern of reinnervation in the striatum is important for development of graft-induced dyskinesia. Neurobiol Dis 2006;21: 657-668.
30. Olanow CW, Freeman TB, Kordower JH. Fetal nigral transplantation as a therapy for Parkinson's disease. Trends Neurosci 1996;19:102-109.
31. Kordower JH, Goetz CG, Freeman TB, Olanow CW. Dopaminergic Transplants in patients with Parkinson's disease: neuroanatomical correlates of clinical recovery. Exp Neurol 1997;144:41-46.
32. Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease: response to chronic administration in 34 patients. Brain 1989;114:601-614.
33. Marion MH, Stocchi F, Quinn NP, et al. Repeated levodopa infusion in fluctuating parkinson's disease: clinical and pharmacokinetic data. Clin Neuropharm 1986;9:165-181.
34. Krack P, Pollak P, Limousin P, Benazzouz A, Deuschl G, Benabid AL. From off-period dystonia to peak-dose chorea. The clinical spectrum of varying subthalamic nucleus activity. Brain 1999;122:1133-1146.
35. Kordower JH, Styren S, DeKosky ST, Olanow CW, Freeman TB. Fetal grafting for Parkinson's disease: expression of immune markers in two patients with functional fetal nigral implants. Cell Transplant 1997;6:213-219.
36. Kordower JH, Chu Y, Hauser RA, Freeman TB, Olanow CW. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nat Med 2008;14:504-506.